2 × TAC → PR/CR: 4 versus 6 × TAC; SD: 4 × TAC versus 4 × NX
pCR 6 versus 8 × TAC: 21 versus 24% (); pCR TAC versus NX: 5 versus 6% ()
cORR 6 versus 8 × TAC: 75 versus 74% (ns); cORR TAC versus NX: both 51% ( for noninferiority = .008); BET 68 versus 59% (); NX less toxic; PFS 6 versus 8 × TAC versus TAC-NX: HR 0.71 (); OS 6 versus 8 × TAC versus TAC-NX: HR 0.79 () Benefit of response-guided therapy derives from HR+ tumors (no benefit for HER2+/HR− and TNBC)